CCDC137: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Target Name: CCDC137

NCBI ID: G339230

CCDC137

CCDC137: A Potential Drug Target and Biomarker for Neurodegenerative Disorders

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the formation of neurofibrillary tangles and senile plaques. These conditions are often treated with drugs that aim to slow down or halt the progression of neurodegeneration. However, the development of drug resistance and the limited efficacy of current treatments make it a significant challenge for researchers to develop new and more effective therapies.

CDC137 is a protein that is expressed in various tissues, including brain, heart, and liver, and has been implicated in the development and progression of neurodegenerative diseases. Its functions include cell signaling, DNA replication, and protein-protein interactions. The protein has also been linked to the formation of neurofibrillary tangles and senile plaques, which are hallmarks of neurodegenerative diseases.

Potential Drug Target

The identification of potential drug targets is an important step in the development of new treatments for neurodegenerative diseases. CCDC137 has been shown to be involved in various cellular processes that are linked to the development of neurodegenerative diseases. Therefore, it is a promising target for drug development.

CDC137 has been shown to play a role in the formation of neurofibrillary tangles, which are composed of abnormal aggregates of the protein tau. The accumulation of tau in the brain is a hallmark of neurodegenerative diseases, and it is thought to contribute to the progressive loss of brain cells.

In addition to its role in neurofibrillary tangles, CCDC137 has also been shown to be involved in the regulation of DNA replication, which is a critical process for the development and maintenance of brain cells. The disruption of DNA replication has been linked to the development of various cancers, including neurodegenerative diseases.

Biomarker

The detection of biomarkers is another important step in the development of new treatments for neurodegenerative diseases. CCDC137 has been shown to be a potential biomarker for the diagnosis and progression of neurodegenerative diseases.

The accumulation of neurofibrillary tangles and senile plaques in the brain is a well-established biomarker for the diagnosis of neurodegenerative diseases. However, the progression of neurodegeneration can be slow, and the development of new biomarkers is important for the early detection and diagnosis of these conditions.

CCDC137 has been shown to be a potential biomarker for the progression of neurodegenerative diseases, as its expression has been observed in the brains of individuals with neurodegenerative diseases. Additionally, the levels of CCDC137 have been shown to be correlated with the severity of neurodegenerative diseases, which suggests that it may be a useful diagnostic tool.

Conclusion

In conclusion, CCDC137 is a protein that has been implicated in the development and progression of neurodegenerative diseases. Its functions include cell signaling, DNA replication, and protein-protein interactions, and it has also been linked to the formation of neurofibrillary tangles and senile plaques, which are hallmarks of these conditions. The potential drug target and biomarker status of CCDC137 make it an attractive target for further research and development. Further studies are needed to fully understand its role in the development and progression of neurodegenerative diseases, as well as its potential as a drug target or biomarker.

Protein Name: Coiled-coil Domain Containing 137

The "CCDC137 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC137 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets